Medical Doctor Program year 2024 Source: CMS Open Payments, 2026 publication

Michael Jordan

Family Medicine Lee, NH Medical Doctor

NPI 1669817821 CMS profile 1752094

65 Calef Hwy Ste 200, Lee, NH 03861

Open in the dashboard

General payments

$3,600

1 record reported · program year 2024

Research payments

$0

Paid to them · None reported · program year 2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Jordan of Lee, NH is reported in the CMS Open Payments database as having received $3,600 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2024 General $3,600 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Jordan
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Michael Jordan were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Michael Jordan Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $3,600 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program year 2024
  1. Sobi, Inc $3,600 1 payment

Every payment, record by record

What the payments were for General payments · program year 2024
  1. Consulting Fee $3,600 1 payment
Products named General payments · program year 2024
  1. GAMIFANT $3,600 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 96 drugs

Part D claims

4,295

Median for Family Practice: 1,826

Drug cost

$310,130

Median for Family Practice: $120,094

Branded share of claims

16.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $94,314
Jardiance Empagliflozin Brand 61 $73,376
Mounjaro Tirzepatide Brand 27 $33,076
Trulicity Dulaglutide Brand 20 $21,061
Eliquis Apixaban Brand 12 $19,075
Linzess Linaclotide Brand 13 $9,196
Albuterol Sulfate Hfa Albuterol Sulfate Brand 114 $4,520
Brilinta Ticagrelor Brand 13 $4,322
Atorvastatin Calcium Generic 472 $4,008
Ondansetron Hcl Generic 27 $3,839

The 10 drugs with the highest cost, of 96 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$56,776

Of which drugs: $10,765

Medicare patients

219

Average age 71

Services billed

726

92 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 42%
Diabetes 24%
Depression 19%
Ischemic heart disease 18%
COPD 15%
Atrial fibrillation 12%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 18 18 $5,202
Sarscv2 vac 30mcg trs-suc im 91320 Office 25 29 $4,236
Vaccine for influenza for injection into muscle 90662 Office 35 36 $1,129

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record